Dogan, E.; Firat, S.T.; Cengiz, M.; Bozkurt, O.; Inanc, M.; Ozkan, M.
The Role of Clinicopathological Features in Tyrosine Kinase Inhibitory Duration in EGFR Mutant Metastatic Non-Small Cell Lung Cancer. J. Clin. Med. 2025, 14, 1149.
https://doi.org/10.3390/jcm14041149
AMA Style
Dogan E, Firat ST, Cengiz M, Bozkurt O, Inanc M, Ozkan M.
The Role of Clinicopathological Features in Tyrosine Kinase Inhibitory Duration in EGFR Mutant Metastatic Non-Small Cell Lung Cancer. Journal of Clinical Medicine. 2025; 14(4):1149.
https://doi.org/10.3390/jcm14041149
Chicago/Turabian Style
Dogan, Ender, Sedat Tarik Firat, Muhammet Cengiz, Oktay Bozkurt, Mevlude Inanc, and Metin Ozkan.
2025. "The Role of Clinicopathological Features in Tyrosine Kinase Inhibitory Duration in EGFR Mutant Metastatic Non-Small Cell Lung Cancer" Journal of Clinical Medicine 14, no. 4: 1149.
https://doi.org/10.3390/jcm14041149
APA Style
Dogan, E., Firat, S. T., Cengiz, M., Bozkurt, O., Inanc, M., & Ozkan, M.
(2025). The Role of Clinicopathological Features in Tyrosine Kinase Inhibitory Duration in EGFR Mutant Metastatic Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 14(4), 1149.
https://doi.org/10.3390/jcm14041149